📣 VC round data is live. Check it out!

Treace Medical Concepts Valuation Multiples

Discover revenue and EBITDA valuation multiples for Treace Medical Concepts and similar public comparables like Onward Medical, Orchestra BioMed, Sight Sciences, Affluent Medical and more.

Treace Medical Concepts Overview

About Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.


Founded

2014

HQ

United States

Employees

477

Website

treace.com

Financials (LTM)

Revenue: $210M
EBITDA: ($5M)

EV

$245M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Treace Medical Concepts Financials

Treace Medical Concepts reported last 12-month revenue of $210M and negative EBITDA of ($5M).

In the same LTM period, Treace Medical Concepts generated $166M in gross profit, ($5M) in EBITDA losses, and had net loss of ($59M).

Revenue (LTM)


Treace Medical Concepts P&L

In the most recent fiscal year, Treace Medical Concepts reported revenue of $213M and EBITDA of ($4M).

Treace Medical Concepts is unprofitable as of last fiscal year, with gross margin of 80%, EBITDA margin of (2%), and net margin of (28%).

See analyst estimates for Treace Medical Concepts
LTMLast FY202320242025202620272028
Revenue$210M$213M$187M$209M$213M
Gross Profit$166M$170M$152M$168M$170M
Gross Margin79%80%81%80%80%
EBITDA($5M)($4M)($39M)($42M)($43M)
EBITDA Margin(2%)(2%)(21%)(20%)(20%)
EBIT Margin(26%)(25%)(27%)(27%)(25%)
Net Profit($59M)($59M)($50M)($56M)($59M)
Net Margin(28%)(28%)(26%)(27%)(28%)
Net Debt-$47M---

Financial data powered by Morningstar, Inc.

Treace Medical Concepts Stock Performance

Treace Medical Concepts has current market cap of $225M, and enterprise value of $245M.

Market Cap Evolution


Treace Medical Concepts' stock price is $3.47.

Treace Medical Concepts share price increased by 0.3% in the last 30 days, and decreased by 40.9% in the last year.

Treace Medical Concepts has an EPS (earnings per share) of $-0.91.

See more trading valuation data for Treace Medical Concepts
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$245M$225M-3.5%0.3%159.7%-40.9%$-0.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Treace Medical Concepts Valuation Multiples

Treace Medical Concepts trades at 1.2x EV/Revenue multiple, and (53.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Treace Medical Concepts

EV / Revenue (LTM)


Treace Medical Concepts Financial Valuation Multiples

As of June 3, 2026, Treace Medical Concepts has market cap of $225M and EV of $245M.

Treace Medical Concepts has a P/E ratio of (3.8x).

LTMLast FY202320242025202620272028
EV/Revenue1.2x1.2x1.3x1.2x1.2x
EV/EBITDA(53.1x)(62.9x)(6.3x)(5.8x)(5.7x)
EV/EBIT(4.5x)(4.5x)(4.8x)(4.4x)(4.5x)
EV/Gross Profit1.5x1.4x1.6x1.5x1.4x
P/E(3.8x)(3.8x)(4.5x)(4.0x)(3.8x)
EV/FCF(12.5x)(9.8x)(5.3x)(5.0x)(8.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Treace Medical Concepts Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Treace Medical Concepts Margins & Growth Rates

Treace Medical Concepts decreased revenue by 3% but EBITDA grew by 44% in the last fiscal year.

In the most recent fiscal year, Treace Medical Concepts reported gross margin of 80%, EBITDA margin of (2%), and net margin of (28%).

See estimated margins and future growth rates for Treace Medical Concepts

Treace Medical Concepts Margins

Last FY202420252026202720282029
Gross Margin80%80%80%78%
EBITDA Margin(2%)(20%)(20%)(3%)
EBIT Margin(25%)(27%)(25%)(26%)
Net Margin(28%)(27%)(28%)(28%)
FCF Margin(12%)(23%)(14%)(6%)

Treace Medical Concepts Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(3%)12%2%(3%)
Gross Profit Growth(5%)11%1%(5%)
EBITDA Growth44%8%2%(87%)
EBIT Growth0%8%(3%)0%
Net Profit Growth(1%)13%6%(1%)
FCF Growth(52%)6%(40%)(59%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Treace Medical Concepts Operational KPIs

Treace Medical Concepts' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.

Treace Medical Concepts' Rule of 40 is (6%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Treace Medical Concepts' Rule of X is (10%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Treace Medical Concepts
LTMLast FY202320242025202620272028
Rule of 40(1%)(6%)---
Bessemer Rule of X1%(10%)---
Revenue per Employee-$0.4M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue66%66%75%71%66%
G&A Expenses to Revenue30%30%25%27%30%
R&D Expenses to Revenue9%10%8%10%10%
Opex to Revenue-105%109%107%105%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Treace Medical Concepts Competitors

Treace Medical Concepts competitors include Onward Medical, Orchestra BioMed, Sight Sciences, Affluent Medical, Utah Medical, Profound Medical, Huons Co, Pro-Dex, Stratec and TriSalus Life Sciences.

Most Treace Medical Concepts public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Onward Medical26.3x15.7x(3.6x)(2.8x)
Orchestra BioMed4.6x7.9x(3.0x)(2.2x)
Sight Sciences2.5x2.4x(7.4x)(7.8x)
Affluent Medical-372.7x-(11.9x)
Utah Medical3.3x-8.8x-
Profound Medical12.1x9.6x(5.3x)(5.8x)
Huons Co0.7x-5.2x-
Pro-Dex3.3x2.9x15.7x-

This data is available for Pro users. Sign up to see all Treace Medical Concepts competitors and their valuation data.

Start Free Trial

Treace Medical Concepts VC Funding History

Before going public, Treace Medical Concepts raised $13M in total equity funding, across 2 rounds.


Treace Medical Concepts Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-17Series A-$6M-Treace Medical Concepts develops surgical solutions for bunions and related midfoot deformities, including the Lapiplasty Procedure. The company has raised a total of $66.5M over 8 funding rounds prior to its IPO. Its IPO in April 2021 raised $106.3M at $17.00 per share, with net proceeds of approximately $107.6M. Revenue reached $92.1M in 2021 and $57.4M in 2020, with later growth to $141.8M in 2022.
Jan-15Seed-$7M-Treace Medical Concepts is a medical technology company focused on bunion correction procedures, including the Lapiplasty® System, which received 510(k) clearance in March 2015 and began sales in September 2015. The company raised a total of $66.5M over 8 funding rounds prior to its IPO. A $50M debt facility was secured with CRG, including $30M at closing and up to $20M more upon milestones, used to retire prior debt, expand sales and marketing, and fund product development. CRG also provided a line of credit. The company completed an IPO on April 23, 2021, raising $106.3M.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Treace Medical Concepts

When was Treace Medical Concepts founded?Treace Medical Concepts was founded in 2014.
Where is Treace Medical Concepts headquartered?Treace Medical Concepts is headquartered in United States.
How many employees does Treace Medical Concepts have?As of today, Treace Medical Concepts has over 477 employees.
Who is the CEO of Treace Medical Concepts?Treace Medical Concepts' CEO is John T. Treace.
Is Treace Medical Concepts publicly listed?Yes, Treace Medical Concepts is a public company listed on Nasdaq.
What is the stock symbol of Treace Medical Concepts?Treace Medical Concepts trades under TMCI ticker.
When did Treace Medical Concepts go public?Treace Medical Concepts went public in 2021.
Who are competitors of Treace Medical Concepts?Treace Medical Concepts main competitors include Onward Medical, Orchestra BioMed, Sight Sciences, Affluent Medical, Utah Medical, Profound Medical, Huons Co, Pro-Dex, Stratec, TriSalus Life Sciences.
What is the current market cap of Treace Medical Concepts?Treace Medical Concepts' current market cap is $225M.
What is the current revenue of Treace Medical Concepts?Treace Medical Concepts' last 12 months revenue is $210M.
What is the current revenue growth of Treace Medical Concepts?Treace Medical Concepts revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of Treace Medical Concepts?Current revenue multiple of Treace Medical Concepts is 1.2x.
Is Treace Medical Concepts profitable?No, Treace Medical Concepts is not profitable.
What is the current EBITDA of Treace Medical Concepts?Treace Medical Concepts has negative EBITDA and is not profitable.
What is Treace Medical Concepts' EBITDA margin?Treace Medical Concepts' last 12 months EBITDA margin is (2%).
What is the current EV/EBITDA multiple of Treace Medical Concepts?Current EBITDA multiple of Treace Medical Concepts is (53.1x).
What is the current FCF of Treace Medical Concepts?Treace Medical Concepts' last 12 months FCF is ($20M).
What is Treace Medical Concepts' FCF margin?Treace Medical Concepts' last 12 months FCF margin is (9%).
What is the current EV/FCF multiple of Treace Medical Concepts?Current FCF multiple of Treace Medical Concepts is (12.5x).
How many companies Treace Medical Concepts has acquired to date?Treace Medical Concepts hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Treace Medical Concepts has invested to date?Treace Medical Concepts hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Treace Medical Concepts

Lists including Treace Medical Concepts

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial